高钠血症供体对肝移植受体围手术期肝功能的影响

王博; 李霄; 张鹏程; 张若涵; 陶开山

doi:10.3969/j.issn.1674-7445.2019.03.015

高钠血症供体对肝移植受体围手术期肝功能的影响

doi: 10.3969/j.issn.1674-7445.2019.03.015

710032 西安，空军军医大学西京医院肝胆外科

基金项目:

国家“973”计划基金资助项目 2015CB554100

家重点研发计划资助项目 2017YFC1103703

国家“863”计划基金资助项目 2012AA021005

国家自然科学基金资助项目 81670593

国家自然科学基金资助项目 81870446

国家自然科学基金资助项目 81300361

国家自然科学基金资助项目 81270549

国家自然科学基金资助项目 81470873

国家自然科学基金资助项目 81671838

陕西省自然科学基础研究计划资助项目 2017JM8014

陕西省社会发展科技攻关项目 2015SF067

西省科技统筹创新工程计划资助项目 2012KTCL03-01

西省科技统筹创新工程计划资助项目 2011KTCL03-15

西京医院学科助推计划基金资助项目 XJZT12M09

西京医院学科助推计划基金资助项目 XJZT13Z01

西京医院学科助推计划基金资助项目 XJZT14Z04

详细信息

作者简介:
王博，男，1994年生，博士研究生，研究方向为器官移植，Email：wabo5227@163.com

通讯作者:
陶开山，男，1966年生，博士，教授，主任医师，研究方向为普通外科与器官移植，Email: taokaishan0686@163.com

中图分类号: R617, R619+.4
计量
- 文章访问数: 265
- HTML全文浏览量: 185
- PDF下载量: 17
- 被引次数: 0
出版历程
- 收稿日期: 2019-03-02
- 网络出版日期: 2021-01-19
- 刊出日期: 2019-05-15

Effect of hypernatremia in donors on perioperative liver function of recipients undergoing liver transplantation

Department of Hepatobiliary Surgery, Xijing Hospital of Air Force Medical University, Xi 'an 710032, China

More Information

Corresponding author: Tao Kaishan, Email: taokaishan0686@163.com

摘要

摘要: 目的探讨高钠血症供体对肝移植受体围手术期肝功能恢复的影响。方法回顾性分析73例肝移植受体资料。根据供体血清钠离子水平将受体分为高钠血症组（供体血清钠≥150 mmol/L，19例）与非高钠血症组（供体血清钠 < 150 mmol/L，54例）。对受体术后1、3、7、14、21 d的血清丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、终末期肝病模型（MELD）评分、白蛋白、总胆红素（TB）、血清肌酐、凝血酶原时间、肝细胞生长因子（HGF）进行检测，对受体术后护肝药使用时间、重症监护室（ICU）住院时间、平均住院时间及并发症发生率进行比较分析。结果与非高钠血症组相比，高钠血症组受体术后1、3、7 d的血清TB、ALT、AST、HGF水平和MELD评分显著升高（均为P < 0.05），而血清白蛋白水平明显降低（均为P < 0.05）。高钠血症组受体术后3、7 d的凝血酶原时间明显长于非高钠血症组（均为P < 0.05）。高钠血症组的受体术后护肝药使用时间和ICU住院时间分别为9（7~13）、11（8~13）d，明显长于非高钠血症组的4（3~9）、7（3~9）d（均为P < 0.05）。两组受体术后平均住院时间、血清肌酐水平、并发症发生率的比较，差异无统计学意义（均为P>0.05）。所有受体均康复出院。结论供体获取前高钠血症对受体围手术期肝功能并无明显影响，但会延长受体术后肝功能的恢复时间。
- 供体 /
- 高钠血症 /
- 肝移植 /
- 肝功能 /
- 围手术期 /
- 肝细胞生长因子 /
- 终末期肝病模型 /
- 凝血酶原时间
Abstract: Objective To evaluate the effect of hypernatremia in donors on perioperative recovery of liver function in the recipients undergoing liver transplantation. Methods Clinical data of 73 liver transplant recipients were analyzed retrospectively. According to the serum levels of sodium in donors, all recipients were divided into hypernatremia group (donor serum sodium ≥150 mmol/L, n=19) and non-hypernatremia group (donor serum sodium < 150 mmol/L, n=54). Serum alanine aminotransferase(ALT), aspartate aminotransferase (AST), model for end-stage liver disease (MELD) score, albumin, total bilirubin (TB), serum creatinine, prothrombin time and hepatocyte growth factor (HGF) in the recipients were detected at 1, 3, 7, 14 and 21 d after liver transplantation. The time of postoperative use of liver-protecting drugs in the recipients, the length of intensive care unit (ICU) stay, the average length of hospital stay and the incidence rate of postoperative complications were statistically compared and analyzed. Results Compared with the non-hypernatremia group, the serum levels of TB, ALT, AST, HGF and MELD scores of the recipients in the hypernatremia group at the postoperative 1, 3 and 7 d were significantly higher (all P < 0.05), whereas the serum albumin level was significantly decreased (P < 0.05). The prothrombin time in the hypernatremia group was significantly longer than that in the non-hypernatremia group at 3 and 7 d after operation (both P < 0.05). In the hypernatremia group, the time of postoperative use of liver-protecting drugs and the length of ICU stay were 9 (7-13) d and 11 (8-13) d, significantly longer than 4 (3-9) d and 7 (3-9) d in the non-hypernatremia group (both P < 0.05). The average length of hospital stay, serum creatinine level and incidence rate of postoperative complications did not significantly differ between two groups (all P>0.05). All recipients were recovered and discharged. Conclusions The hypernatremia in donors exert no significant effect on the perioperative liver function of the recipients, whereas it can prolong the postoperative recovery time of liver function of the recipients.
- Donor /
- Hypernatremia /
- Liver transplantation /
- Liver function /
- Perioperative period /
- Hepatocyte growth factor /
- Model for end-stage liver disease /
- Prothrombin time

HTML全文

图 1 两组受体术后血清总胆红素、转氨酶和白蛋白水平的比较

Figure 1. Comparison of serum total bilirubin, transaminase and albumin levels after operation of recipients between two groups

下载: 全尺寸图片幻灯片

图 2 两组受体术后血清肌酐水平的比较

Figure 2. Comparison of serum creatinine levels of recipients between two groups after operation

下载: 全尺寸图片幻灯片

参考文献(20)

[1]	NEMES B, GÁMÁN G, POLAK WG, et al. Extended criteria donors in liver transplantation part Ⅰ: reviewing the impact of determining factors[J]. Expert Rev Gastroenterol Hepatol, 2016, 10(7):827-839. DOI: 10.1586/17474124.2016.1149061.
[2]	NEMES B, GÁMÁN G, POLAK WG, et al. Extended-criteria donors in liver transplantation part Ⅱ: reviewing the impact of extended-criteria donors on the complications and outcomes of liver transplantation[J]. Expert Rev Gastroenterol Hepatol, 2016, 10(7):841-859. DOI: 10.1586/17474124.2016.1149062.
[3]	BENKO T, GALLINAT A, MINOR T, et al. The postoperative model for end stage liver disease score as a predictor of short-term outcome after transplantation of extended criteria donor livers[J]. Eur J Gastroenterol Hepatol, 2017, 29(6):716-722. DOI: 10.1097/MEG.0000000000000851.
[4]	KNAAK M, GOLDARACENA N, DOYLE A, et al. Donor BMI > 30 is not a contraindication for live liver donation[J]. Am J Transplant, 2017, 17(3):754-760. DOI: 10.1111/ajt.14019.
[5]	MAZAHERI M, MOJTABAEE M, MOHSENZADEH M, et al. Liver donation from marginal donors: to donate or not to donate? [J]. Exp Clin Transplant, 2019, 17(Suppl 1):254-256. DOI: 10.6002/ect.MESOT2018.P112.
[6]	SAIDI RF. Utilization of expanded criteria donors in liver transplantation[J]. Int J Organ Transplant Med, 2013, 4(2):46-59. http://d.old.wanfangdata.com.cn/OAPaper/oai_doaj-articles_51eba3906b025a150d904fb7e2555d28
[7]	LOZANOVSKI VJ, KHAJEH E, FONOUNI H, et al. The impact of major extended donor criteria on graft failure and patient mortality after liver transplantation[J]. Langenbecks Arch Surg, 2018, 403(6):719-731. DOI: 10.1007/s00423-018-1704-z.
[8]	FRANZINI M, GHINOLFI D, PEZZATI D, et al. Development of a normothermic extracorporeal liver perfusion system toward improving viability and function of human extended criteria donor livers[J]. Liver Transpl, 2016, 22(11):1615-1616. DOI: 10.1002/lt.24601.
[9]	BURLAGE LC, KARIMIAN N, WESTERKAMP AC, et al. Oxygenated hypothermic machine perfusion after static cold storage improves endothelial function of extended criteria donor livers[J]. HPB (Oxford), 2017, 19(6):538-546. DOI: 10.1016/j.hpb.2017.02.439.
[10]	ROUTH D, SHARMA S, NAIDU CS, et al. Comparison of outcomes in ideal donor and extended criteria donor in deceased donor liver transplant: a prospective study[J]. Int J Surg, 2014, 12(8):774-777. DOI: 10.1016/j.ijsu.2014.06.003.
[11]	PARK GC, SONG GW, MOON DB, et al. A review of current status of living donor liver transplantation[J]. Hepatobiliary Surg Nutr, 2016, 5(2):107-117. DOI: 10.3978/j.issn.2304-3881.2015.08.04.
[12]	GUARRERA JV, HENRY SD, SAMSTEIN B, et al. Hypothermic machine preservation facilitates successful transplantation of " orphan" extended criteria donor livers[J]. Am J Transplant, 2015, 15(1):161-169. DOI: 10.1111/ajt.12958.
[13]	JADLOWIEC CC, TANER T. Liver transplantation: current status and challenges[J]. World J Gastroenterol, 2016, 22(18):4438-4445. DOI: 10.3748/wjg.v22.i18.4438.
[14]	VODKIN I, KUO A. Extended criteria donors in liver transplantation[J]. Clin Liver Dis, 2017, 21(2):289-301. DOI: 10.1016/j.cld.2016.12.004.
[15]	DIRICAN A, OZSOY M, ATES M, et al. Consequences of the use of extended criteria donors in living donor liver transplantation[J]. Ann Transplant, 2015, 20:211-217. DOI: 10.12659/AOT.892454.
[16]	KASEJE N, MCLIN V, TOSO C, et al. Donor hypernatremia before procurement and early outcomes following pediatric liver transplantation[J]. Liver Transpl, 2015, 21(8):1076-1081. DOI: 10.1002/lt.24145.
[17]	FOGUET C, MARIN S, SELIVANOV VA, et al. HepatoDyn: a dynamic model of hepatocyte metabolism that integrates 13C isotopomer data[J]. PLoS Comput Biol, 2016, 12(4):e1004899. DOI: 10.1371/journal.pcbi.1004899.
[18]	SAHI J, GREPPER S, SMITH C. Hepatocytes as a tool in drug metabolism, transport and safety evaluations in drug discovery[J]. Curr Drug Discov Technol, 2010, 7(3):188-198. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=7b74305473f6fa1bfd8b6ce3ec25b736
[19]	BIFULCO M, PISANTI S, CIAGLIA E. The complex interplay among hepatocytes and immune cells at the crossroad between inflammation and cholesterol metabolism in hyperglycemia[J]. Endocrine, 2017, 58(1):21-23. DOI: 10.1007/s12020-017-1254-0.
[20]	YUAN X, HUANG H, HUANG Y, et al. Nuclear factor E2-related factor 2 knockdown enhances glucose uptake and alters glucose metabolism in AML12 hepatocytes[J]. Exp Biol Med (Maywood), 2017, 242(9):930-938. DOI: 10.1177/1535370217694435.